06/16/2026
📉 ApoB: The Stronger Evidence Wins
The data for lowering ApoB (via statins, ezetimibe, PCSK9i, etc.) is rock-solid and backed by decades of high-quality research. The idea that high ApoB is “fine if you’re lean and fit” (e.g. LMHR/keto crowd) is still just a hypothesis with weak, conflicting support.
✅ Evidence for Lowering ApoB
-Plaque regression trials (GLAGOV, ASTEROID, SATURN, HUYGENS): Intensive lowering (ApoB often 2 million people confirm ApoB particles are directly causal in atherosclerosis. “The lower, the better” holds down to very low levels.
- Outcomes: Fewer events when ApoB drops. This is foundational cardiology, not fringe.
Mechanistically: Fewer ApoB particles = less cholesterol delivery into artery walls = less inflammation & plaque progression.
❌ “High ApoB is benign if lean/fit”
This relies heavily on small, short-term observational data like re-analyzed KETO-CTA (~100 people, very high ApoB, low baseline plaque, ~1 year follow-up). Some stability seen, but:
- No control group
- Short duration
- Narrow high-ApoB range (can’t test causality)
- Methodological issues
Some interpretations even showed worsening of plaque in such a short study in some participants.
Broader genetic & epidemiologic evidence shows lifelong high ApoB increases risk regardless of leanness. Metabolic health helps overall risk but does not fully cancel ApoB’s causal effect.
The Key Asymmetry
Lowering ApoB has direct, replicable proof of reversing disease in arteries.
The “it’s fine if you’re shredded” claim rests on absence of strong signal in one atypical short study.
Bottom line: Metabolic health is great, but the weight of evidence strongly favors keeping ApoB low for minimal lifetime cardiovascular risk. Betting against it long-term is risky when proven tools exist.
What’s your ApoB? Drop it below 👇